Co-SAM: An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated Severe Acute Malnutrition
概览
- 阶段
- 3 期
- 干预措施
- Standard Care
- 疾病 / 适应症
- Severe Acute Malnutrition
- 发起方
- Queen Mary University of London
- 入组人数
- 674
- 试验地点
- 9
- 主要终点
- Death or first hospitalisation or failed nutritional recovery within 24 weeks post-randomisation
- 状态
- 进行中(未招募)
- 最后更新
- 2个月前
概览
简要总结
Malnutrition underlies 45% of child deaths, and has far-reaching educational, economic and health consequences. Severe acute malnutrition (SAM) affects 17 million children globally and is the most life-threatening form of malnutrition. Community-based management of acute malnutrition using ready-to-use therapeutic food (RUTF) has transformed outcomes for children with uncomplicated SAM, but those presenting with poor appetite or medical complications (categorised as having 'complicated' SAM) require hospitalisation. Data show that pneumonia, diarrhoea and malaria are leading causes of death in children with complicated SAM after discharge from hospital. High risk of infectious deaths suggests that sustained antimicrobial interventions may reduce mortality following discharge from hospital. Furthermore, children with complicated SAM respond less well to nutritional rehabilitation, and oftentimes are discharged to a home environment characterised by poverty and multiple caregiver vulnerabilities including depression, low decision making autonomy, lack of social support, gender-restricted family relations, and competing demands on scarce resources. Caregivers have to navigate diverse challenges that impede engagement with clinical care after discharge from hospital. The objective is to address the biological and social determinants of multimorbidity in children with complicated SAM by comparing an antimicrobial intervention with standard of care.
详细描述
This is a 2-arm randomized, unblinded clinical trial comparing: Arm 1: Standard-of-care (control) Arm 2: Antimicrobial package Arm 3: Psychosocial package Arm (terminated early). The trial will test the superiority of each intervention arm over the standard of care arm (control). Children in the control arm (and all intervention arms) will receive RUTF for at least 2 weeks and all standard care. The trial is adaptive, meaning i) that each intervention arm will be added as it becomes available, and ii) an interim analysis will enable us to drop arms which are unpromising based on pre-specified criteria. There will be no blinding or placebo, because the very different components in each trial arm make it very challenging to blind. Children with complicated SAM will be screened and enrolled from hospital sites shortly before discharge, and interventions will be started before leaving hospital, and continued for 12 weeks through outpatient visits. Children will be followed at 2, 4, 6, 8, 12 and 24 weeks post-discharge in dedicated study clinics (with additional visits at 1, 3 and 5 weeks for caregiver-child pairs receiving the psychosocial intervention). The primary outcome is death or hospitalization or failed nutritional recovery by 24 weeks. 674 children have been recruited across three countries. The study is not testing new drugs but rather testing a different package of medications as compared to current standard care, which the investigator believe will have greater benefit. The Psychosocial intervention (terminated early) will involve three components: i) The Friendship Bench, which was developed in Zimbabwe as a low-cost psychological intervention utilising problem-solving therapy (delivered by trained lay workers) and peer-to-peer support to address depression and other common mental disorders. There is a strong evidence-base for its use in urban LMIC settings. Peer support groups meet every 1-2 weeks and focus on communal problem solving, and establishing income-generation activities (such as making bags). ii) Care for Child Development is a UNICEF package that helps families build stronger relationships and solve problems in caring for the child at home, through play and communication activities to stimulate children, through a series of age-appropriate interactive modules delivered by a lay worker using 'flash' cards. It has been used in other African contexts and has good acceptability. iii) Educational and behavior-change messages around better nutrition; play for children with SAM; stigma, HIV and gender-based violence; financial planning; causes of SAM; and health-seeking behaviours. Blood and stool will be collected at baseline, 12 and 24 weeks from all children to explore recovery of underlying pathological processes. At week 2, liver function tests will be undertaken in local laboratories. Samples will also be transported to Kenya and the Netherlands for some assays not available in each country.
研究者
入排标准
入选标准
- •Age 6-59 months, of either sex
- •Hospitalised with complicated severe acute malnutrition, as per WHO definition
- •Started transition to RUTF
- •Caregiver willing and able to attend the study clinic for all visits
- •Caregiver able and willing to give informed consent
排除标准
- •Any acute or chronic condition which mean that receipt of one or more study interventions, or participation in the trial, would not be advisable.
研究组 & 干预措施
Arm 1: Standard-of-care (control)
Children in the control arm will receive Ready to Use Therapeutic Food (RUTF) for at least 2 weeks, plus all standard care. Children with HIV will receive long-term Cotrimoxazole prophylaxis and antiretroviral therapy, as per current guidelines.
干预措施: Standard Care
Arm 2: Antimicrobial package
Children will receive a bundle of azithromycin (3 days every month), isoniazid (daily), rifampicin (daily) and pyridoxine (daily) for 12 weeks.
干预措施: Rifampicin
Arm 2: Antimicrobial package
Children will receive a bundle of azithromycin (3 days every month), isoniazid (daily), rifampicin (daily) and pyridoxine (daily) for 12 weeks.
干预措施: Azithromycin
Arm 2: Antimicrobial package
Children will receive a bundle of azithromycin (3 days every month), isoniazid (daily), rifampicin (daily) and pyridoxine (daily) for 12 weeks.
干预措施: Isoniazid
Arm 2: Antimicrobial package
Children will receive a bundle of azithromycin (3 days every month), isoniazid (daily), rifampicin (daily) and pyridoxine (daily) for 12 weeks.
干预措施: Pyridoxine Hydrochloride
Arm 2: Antimicrobial package
Children will receive a bundle of azithromycin (3 days every month), isoniazid (daily), rifampicin (daily) and pyridoxine (daily) for 12 weeks.
干预措施: Standard Care
结局指标
主要结局
Death or first hospitalisation or failed nutritional recovery within 24 weeks post-randomisation
时间窗: 24 weeks post-randomisation
a) All-cause mortality. b) Overnight admission to a health facility for any reason. This includes cases where there was a clinical plan to hospitalise the child, which was refused by the caregiver. c) Failed nutritional recovery is defined as either: i) Persistent WHZ\<-2 or MUAC\<12.5cm or bilateral pedal oedema at week 12; or ii) WHZ\<-2 or MUAC\<12.5cm or bilateral pedal oedema at any time between baseline and week 24 post-randomisation in a child who had previously recovered.
次要结局
- Change in weight-for-age Z-score(24 weeks post-randomisation)
- Number of participants with suspected or confirmed tuberculosis,pneumonia, diarrhoea or malaria(24 weeks post-randomisation)
- Change in mid-upper arm circumference(24 weeks post-randomisation)
- Change in weight-for-height Z-score(24 weeks post-randomisation)
- Change in height-for-age Z-score(24 weeks post-randomisation)